Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 188.60B |
| Revenue (ttm) | 42.26B |
| Net Income (ttm) | 13.89B |
| Shares Out | n/a |
| EPS (ttm) | 3.12 |
| PE Ratio | 13.57 |
| Forward PE | 12.81 |
| Dividend | 1.56 (3.68%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 261,018 |
| Average Volume | 515,334 |
| Open | 41.97 |
| Previous Close | 41.69 |
| Day's Range | 41.75 - 43.03 |
| 52-Week Range | 35.76 - 107.00 |
| Beta | 0.35 |
| RSI | 48.95 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Why Novo Nordisk Stock Just Hit a 4-Year Low
Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.
Novo Nordisk: Headwinds On The Surface, Deep Value If You Dig
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of 1...
Novo Nordisk: A Textbook Value Trap
Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform w...
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results
The company revealed critical information that investors will not want to miss.
How Medicare's new drug prices could reshape Novo Nordisk and european pharma
Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk's blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts...
Why Novo Nordisk Stock Is Moving Higher Today
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The application is under expedited FDA review, with a decision expected within one to two...
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
On Wednesday, Novo Nordisk A/S (NYSE: NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic...
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from ...
Novo Nordisk Seeks FDA Approval of Higher Dose of Wegovy Weight-Loss Shot
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.
Novo shares rise as US Medicare price cuts come in largely as expected
Novo Nordisk shares rose 5% on Wednesday after analysts said that U.S. price cuts for the Danish drugmaker's semaglutide came in broadly as expected.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O...
Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter
Novo Nordisk A/S (NYSE: NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to brea...
Here's Why Novo Nordisk Stock Popped Today
The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes. The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial fo...
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Novo Nordisk A/S (NYSE: NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's ...
Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill
Novo Nordisk A/S remains the market leader in obesity and diabetes treatments, despite a recent sharp stock drop and failed Alzheimer's trial. The real growth catalyst for NVO is the upcoming oral sem...
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk A/S (NYSE: NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.
Final Trade: BABA, ZM, NVO, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
What's Happening With Novo Nordisk Stock?
Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly st...
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth Buying
Novo Nordisk A/S shares fell after phase 3 trials showed semaglutide did not slow Alzheimer's progression, though the trials were a longshot due to low optimism. NVO remains fundamentally strong, with...
Novo Nordisk: The Fundamental Story Remains Strong, So I Bought More
Novo Nordisk faces negative headlines, but recent share price weakness presents a compelling long-term buying opportunity. NVO's failed Alzheimer's trial, restructuring, and price cuts have pressured ...
Novo Nordisk's weight-loss-drug trial provides rare good news in a rocky year
Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development.
Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.